Search Results

Eyenuk has received U.S. Food and Drug Administration (FDA) clearance to use the Topcon NW400 retinal camera with its EyeArt AI system to automatically detect diabetic retinopathy (DR), adding to the already-cleared usage with Canon CR-2 AF and Canon CR-2 Plus AF cameras.

Eyenuk has been approved to market its EyeArt® AI eye screening system in the European Union for the new uses of detecting age-related macular degeneration (AMD) and glaucomatous optic nerve damage (a sign of glaucoma).

Eyenuk, Inc. from the EyeArt prospective, multicenter pivotal clinical trial were published as an original investigation in JAMA Network Open, a peer-reviewed medical journal published by the American Medical Association. The article is titled “ Pivotal Evaluation of

Eyenuk, Inc. , a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening, today announced strong business growth even as the COVID-19 pandemic is putting pressure on the healthcare systems worldwide.

Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening, today announced that it has completed a financing round of US$6.2 million led by AXA IM, through AXA IM Alts, a global leader in alternative investments with c. €162 billion of assets under management1

Eyenuk, Inc., a global artificial intelligence medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced that it completed the first quarter of 2020 with encouraging business results.

Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimer’s disease.

Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today results from its landmark prospective, multi-center, pivotal clinical trial to validate the EyeArt® AI Eye Screening System for autonomous detection of diabetic retinopathy (DR), a blinding disease estimated to affect 191 million people globally by the year 2030

University of Genoa Team Presented Strong EyeArt Results at the Macula in Liguria 2020 Conference